Status and phase
Conditions
Treatments
About
Participants responding well in Study FE200486 CS06 (NCT00117949) were given the opportunity to continue treatment with degarelix under a clinical study until FE200486 was available on the market or until the study was discontinued.
Study FE200486 CS06A was to provide knowledge of the long-term safety and tolerability of FE200486.
Full description
The data include participants from both the main study (FE200486 CS06; NCT00117949) and the extension study FE200486 CS06A.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Each patient must meet the following inclusion criteria before entry into the study:
Exclusion criteria
Any patient meeting any of the following exclusion criteria will not be entered into the study:
Primary purpose
Allocation
Interventional model
Masking
37 participants in 4 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal